Autoimmune diseases like systemic lupus erythematosus (SLE) disproportionately affect women, especially those that identify as Black or Latinx, more than men. However, all patients diagnosed with SLE are treated with the same immunotherapies. BroadIgnite funding will allow Ayshwarya to deploy single-cell sequencing and computational methods and dissect such phenotypic heterogeneity, paving the way for personalized treatments that better manage patients’ symptoms.